The Medical Letter®

on Drugs and Therapeutics

Volume 66 **June 10, 2024**

ISSUE No. 1704

IN THIS ISSUE

The Medical Letter®
on Drugs and Therapeutics

Volume 66 (Issue 1704) June 10, 2024

Addendum: *Relyvrio* Withdrawn

Relyvrio, the fixed-dose combination of sodium phenyl-butyrate and taurursodiol that received accelerated approval for treatment of amyotrophic lateral sclerosis (ALS) in 2022 based on a phase 2 trial showing that it slowed functional decline,[1] has voluntarily been withdrawn from the market. According to the manufacturer (Amylyx), the decision to withdraw *Relyvrio* was based on the results of a phase 3, 48-week trial (PHOENIX). The change from baseline on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, which measures fine motor, gross motor, bulbar, and respiratory functioning, was not statistically significantly greater with *Relyvrio* than with placebo.[2] Patients who are already taking the combination will be able to receive the drug from the manufacturer free of charge.

1. Relyvrio for ALS. Med Lett Drugs Ther 2022; 64:190.
2. LH van den Berg. PHOENIX. Results from a global phase 3 trial evaluating an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis. Available at: https://bit.ly/4dU0mCo. Accessed May 22, 2024.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):
1 year - $159; 2 years - $298;
3 years - $398. $65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - $45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected: